Critique of apixaban versus warfarin in patients with atrial fibrillation.
Department of Neurology, Triemli Hospital, Birmensdorferstrasse 497, CH-8063 Zurich, Switzerland. krassen.nedeltchev@triemli.stzh.ch
Krassen
K
Nedeltchev
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D017327:Clinical Trials, Phase IV as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D014859:Warfarin